storage stability comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-10-14. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
The new 34th district stretches from Brownsville in the Rio Grande Valley, northward along the Gulf Coast to most of Corpus Christi, covering all of Cameron, Willacy, Kenedy, Kleberg and most of Nueces counties, essentially a recreation of the old 27th district from its establishment in 1982 until the 2010 election. The incumbent is Democrat Vicente Gonzalez, who was re-elected with 51.3% of the vote in 2024. Donald Trump won the district with 54.6% of the vote in 2024, having previously lost the district to Hillary Clinton and Joe Biden in 2016 and 2020, respectively, with Barack Obama winning the district twice in 2008 and 2012. Also, Ted Cruz won the district with a 49.7% plurality in 2024, even though the district gave 55% of the vote to Beto O'Rourke over Cruz in 2018.
== Discovery == The discovery of KLB represents an example of a “genome mining” approach. Cluster of genes encoding KLB biosynthetic pathway was found in genome database using low-level homology of one of the proteins to microcin B17 synthetase. Cloning and expression of cluster in a heterologous host (Escherichia coli) yielded the active compound. The name given to the compound reflects the original bacterium where the biosynthetic cluster was found (Klebs-) and the presence of azole cycles (-azolicin).
The natural alternate splicing of the RET gene results in the production of 3 different isoforms of the protein RET. RET51, RET43, and RET9 contain 51, 43, and 9 amino acids in their C-terminal tail, respectively. The biological roles of isoforms RET51 and RET9 are the most well studied in vivo, as these are the most common isoforms in which RET occurs. RET is the receptor for members of the glial cell line-derived neurotrophic factor (GDNF) family of extracellular signalling molecules or ligands (GFLs). In order to activate RET, first GFLs must form a complex with a glycosylphosphatidylinositol (GPI)-anchored co-receptor. The co-receptors themselves are classified as members of the GDNF receptor-α (GFRα) protein family. Different members of the GFRα family (GFRα1-GFRα4) exhibit a specific binding activity for a specific GFLs. Upon GFL-GFRα complex formation, the complex then brings together two molecules of RET, triggering trans-autophosphorylation of specific tyrosine residues within the tyrosine kinase domain of each RET molecule. Phosphorylation of these tyrosines then initiates intracellular signal transduction processes.
Sources: en.wikipedia.org
=== Government agencies === Agricultural Adjustment Administration, a 1933–1942 U.S. government agency Puerto Rico Aqueduct and Sewer Authority (Spanish: Autoridad de Acueductos y Alcantarillados de Puerto Rico) Ainmean-Àite na h-Alba, the national advisory partnership for Scottish Gaelic place names in Scotland
(In the 1970s and 1980s, Heseltine's conference speech was often the highlight of the Conservative Party Conference, despite his views being well to the left of the then leader Margaret Thatcher.) He was eventually elected to the Library Committee of the Oxford Union for Hilary (Spring) Term 1953. The Oxford Union minutes record after a debate on 12 February 1953 that "Mr Heseltine should guard against artificial mannerisms of voice and calculated flourishes of self-conscious histrionics; this is only worth saying because he has the makings of a first class speaker". Heseltine was then elected to the Standing Committee of the Oxford Union for Trinity (summer) Term 1953. On 30 April 1953 he opposed the setting up of the Western European Union (a European defence treaty), not least because it might antagonise the USSR following the supposed "recent change of Soviet attitudes" (i.e. after Stalin's death). On 4 June 1953, he called for the development of the British Commonwealth as a third major power in the world (after the US and USSR). At the end of that summer term he stood unsuccessfully for the Presidency but was instead elected to the top place on the committee. In his third year (1953–54) he served in top place on the committee, then as Secretary, and finally as Treasurer. As Treasurer he attempted to solve the Union's financial problems not by cost-cutting but by an ultimately successful "Brighter Union" policy of bringing in more students for food and drink, and by converting the Union cellars into a venue for events.
β-Amanitin (beta-Amanitin) is a cyclic peptide comprising eight amino acids. It is part of a group of toxins called amatoxins, which can be found in several mushrooms belonging to the genus Amanita. Some examples are the death cap (Amanita phalloides) and members of the destroying angel complex, which includes A. virosa and A. bisporigera. Due to the presence of α-Amanitin, β-Amanitin, γ-Amanitin and epsilon-Amanitin these mushrooms are highly lethal to human beings.
Sources: en.wikipedia.org
The glial protein most severely affected is FABP5. Another study showed that 100% of hippocampal astrocytes that contain FABP7 also contain FABP5. These data suggest that FABP7+/Gomori-positive astrocytes may play a role in Alzheimer's disease. An altered glial function in this region could compromise the function of dentate gyrus neurons and also the function of axons that terminate in the dentate gyrus. Many such axons originate in the lateral entorhinal cortex, which is the first brain region to show degeneration in Alzheimer's disease. Astrocyte pathology in the hippocampus thus might make a contribution to the pathology of Alzheimer's disease.
The newer drugs have a better bioavailability as they are not charged and have a non-ionic interaction to the S1 pocket. Rivaroxaban During the SAR development of rivaroxaban, researchers realized that adding a 5-chlorothiophene-2-carboxamide group to the oxazolidonine core could increase the potency by 200 fold, which had previously been too weak for medical use. In addition to this discovery, a clear preference for the (S)-configuration was confirmed. This compound had a promising pharmacokinetical profile and did not contain a highly basic amidine group, but that had previously been considered important for the interaction with the S1 pocket. These findings lead to extensive SAR (structure-activity relationship) researches. During the SAR testing, R1 was defined as the most important group for potency. Pyrrolidinone was the first R1 functional group to significantly increase the potency but further researches revealed even higher potency with a morpholinone group instead. Groups R2 and R3 had hydrogen or fluorine attached and it was quickly assessed that having hydrogen resulted in highest potency. Groups R2 and R3 were then substituted for various groups, which were all less potent than the hydrogen, so hydrogen was the final result. As the chlorothiophene moiety had an inadequate water solubility, substituting it with another group was attempted but was unsuccessful. The chlorothiophene moiety binds to Tyr-228 at the bottom of the S1 pocket, making it a key factor regarding binding to FXa. Rivaroxaban has both high affinity and good bioavailability.
== Bibliography == Borgelt LM, O'Connell MB, Smith JA, Calis KA (2010). Women's Health Across the Lifespan: A Pharmacotherapeutic Approach. ASHP. pp. 513–. ISBN 978-1-58528-194-7. Greenberger NJ, Blumberg R, Burakoff R, eds. (23 April 2009). Current Diagnosis and Treatment in Gastroenterology, Hepatology, and Endoscopy. McGraw Hill Professional. pp. 282–. ISBN 978-0-07-149007-8. South-Paul JE, Matheny SC, Lewis EL (4 September 2007). Current Diagnosis & Treatment in Family Medicine (Second ed.). McGraw-Hill Companies. ISBN 978-0-07-146153-5. Potts JM, ed. (2008). Genitourinary Pain and Inflammation: Diagnosis and Management. Springer. pp. 121–. ISBN 978-1-58829-816-4. Zderic S, Kirk J (15 September 2008). Pediatric Urology for the Primary Care Provider. Thoroughfare, NJ: SLACK Incorporated. pp. 22–. ISBN 978-1-55642-785-5.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.